Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET).
Conference call and webcast:The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.
Pre-registration:Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants are encouraged to pre-register for the conference call using the following link:STVN conference call pre-registration.
Webcast:A live, listen-only webcast of the call will be available at the following link:STVN Q3 2024 Webcast
Dial in: Those who are unable to pre-register may dial in by calling:
Italy: | +39 02 802 09 11 |
United Kingdom: | +44 1 212 818004 |
United States: | +1 718 705 8796 |
United States Toll Free: | +1 855 265 6958 |
Questions during the call:Participants who wish to ask questions during the call should use the HD webphone link:https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=
Replay:
The webcast will be archived for three months on the Investor Relations section of the Company’s website.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions, as well as engineering solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug lifecycle from development to clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients. For more information, please visitwww.stevanatogroup.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20241022517591/en/
Investor RelationsLisa Mileslisa.miles@stevanatogroup.com
Source: Stevanato Group S.p.A.
Released October 22, 2024